Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04837430
Status:
RECRUITING
Last Update Posted:
2023-09-22
First Post:
2021-04-03
Brief Title:
NT-proBNP and Troponin I in Dengue Children
Sponsor:
Le Phuoc Truyen
Organization:
University of Medicine and Pharmacy at Ho Chi Minh City
Study Overview
Official Title:
NT-proBNP and Troponin I in Children With Dengue Hemorrhagic Shock a Longitudinal Study
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To discribe concentration of NT-proBNP and Troponin I in Dengue hemorrhagic shock children in correlation between concentration of NT-proBNP and troponin I with total fluid admission respiratory support using inotrope and vasopressor using
Detailed Description:
Treatment of children with Dengue hemorrhagic shock syndrome DSS is challenge especially in cases with hypotensive shock profound shock or whom do not have a response to initial crystalloid therapy Currently treatment of DSS remains almost supportive with particular emphasis on careful fluid management However fluid overload is a common complication of this treatment lead to many difficulties in management of severe Dengue children accompany with morbidity and mortality Diagnosis of fluid overload mostly based on clinical features and chest X-ray or ultrasound Until now no biomarker are widely using for diagnosis of fluid overload in clinical NT-proBNP is secreted when stretching the wall of the cardiac muscle This may a suitable biomarker to discover the fluid overload state in children with DSS Troponin I is a biomarker of cardiac muscle damage
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None